Aichi

Running trials

• Recruiting

  Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer

  NCT07710885· Phase 3· Source

• Active, not recruiting

  TEZSPIRE (Tezepelumab) Asthma Japan Post-Marketing Study (PMS)

  NCT05729711· Source

• Active, not recruiting

  SAPHNELO Systemic Lupus Erythematosus Japan Post-Marketing Surveillance (PMS)

  NCT05141201· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Liver and biliary tract cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Study to Evaluate the Association of Biliary Complications and Treatment Duration in Unresectable BTC Patients

  NCT07101874· Source

• Completed

  Calquence CLL 1L Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study

  NCT05665374· Source

• Completed

  Imfinzi BTC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEI

  NCT05835778· Source

• Completed

  Imfinzi/Imjudo NSCLC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEI

  NCT05826366· Source

• Completed

  LYNPARZA Breast Cancer in the Adjuvant Setting Japan Post-Marketing Surveillance (PMS)

  NCT05677308· Source

• Completed

  Forxiga CKD Japan Post-Marketing Surveillance (PMS)

  NCT05306210· Source

• Completed

  Calquence CLL rr Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - All Patient Investigation

  NCT04872621· Source

• Completed

  LYNPARZA Pancreas Cancer Japan Post-Marketing Surveillance (PMS)

  NCT04889404· Source

• Completed

  Forxiga HF General Drug Use-Results Study

  NCT04865406· Source

• Completed

  FASENRA SCEI for Long-term Use

  NCT03588546· Source

• Completed

  Brilinta Clinical Experience Investigation

  NCT03212287· Source